| Theme | The Current Status of Management of Gallbladder Cancer | |
|---|---|---|
| Title | Chemotherapy for Gallbladder Cancer | |
| Publish Date | 2019/02 | |
| Author | Takashi Kurosawa | Department of Medical Oncology, Kyorin University School of Medicine |
| Author | Naohiro Okano | Department of Medical Oncology, Kyorin University School of Medicine |
| Author | Fumio Nagashima | Department of Medical Oncology, Kyorin University School of Medicine |
| Author | Junji Furuse | Department of Medical Oncology, Kyorin University School of Medicine |
| [ Summary ] | Gallbladder cancer is a form of biliary tract cancer (BTC), and prognosis remains extremely poor. Treatments for unresectable or recurrence of BTC are limited, and there are a few chemotherapeutic agents compared to those available for other gastrointestinal cancers. A gemcitabine plus cisplatin regimen has been recognized as the standard chemotherapy for advanced BTC. In Japan, S-1 has also been approved for BTC and is often used for seond-line chemotherapy. Furthermore, S-1 containing regimens have recently been investigated for first-line chemotherapy. Although adjuvant chemotherapy after surgery or the second-line chemotherapy has not been established, some clinical trials in adjuvant or the second-line settings are currently ongoing. Some molecular targeted agents and immune checkpoint inhibitors are also under investigation for BTC. It is expected that new treatment strategies based on biomarkers may be established in the near future. | |